# PLAGL2

## Overview
PLAGL2 (PLAG1 like zinc finger 2) is a gene that encodes a zinc finger transcription factor involved in various cellular processes, including cell proliferation, differentiation, and apoptosis. The protein product of PLAGL2 is characterized by its C2H2-type zinc finger motifs, which facilitate its role in DNA binding and transcriptional regulation. As a transcription factor, PLAGL2 is implicated in both tumor suppressive and oncogenic pathways, depending on the cellular context. It can induce cell cycle arrest and apoptosis through the upregulation of p73 and other proapoptotic proteins, while also being associated with cancer progression in certain malignancies, such as glioblastoma and colorectal cancer. The protein's activity is modulated by post-translational modifications, including sumoylation and acetylation, which influence its transcriptional activity and subnuclear localization (Zheng2005Sumoylation; Mizutani2002A; Kas1998Transcriptional).

## Structure
PLAGL2 is a zinc finger protein characterized by its C2H2-type zinc finger motifs, which are crucial for its DNA-binding capabilities. The protein consists of 496 amino acids, with a prominent amino-terminal region containing six C2H2 zinc fingers that follow a consensus sequence (Kas1998Transcriptional). The carboxyl-terminal region of PLAGL2 is proline- and serine-rich and includes an essential activation domain located between Pro-382 and Gln-496 (Kas1998Transcriptional). This region is less conserved compared to the zinc finger domain but contains a conserved stretch of four amino acids (STSY) that may serve as a phosphorylation site (Kas1998Transcriptional).

Post-translational modifications play a significant role in regulating PLAGL2's function. Sumoylation at specific lysine residues (Lys 250, Lys 269, and Lys 356) represses its transcriptional activity and affects its subnuclear localization, with sumoylation-deficient mutants localizing to the nucleoli (Zheng2005Sumoylation). Acetylation, in contrast, enhances PLAGL2's transactivation potential (Zheng2005Sumoylation). These modifications highlight the complex regulatory mechanisms controlling PLAGL2's activity and localization. The protein's structure and modifications suggest its involvement in transcriptional regulation and potential roles in cellular processes such as apoptosis and cancer (Mizutani2002A).

## Function
PLAGL2 (PLAG1 like zinc finger 2) is a transcription factor involved in regulating gene expression, particularly in the context of cell proliferation, differentiation, and apoptosis. In healthy human cells, PLAGL2 can induce cell cycle arrest and apoptosis, suggesting a potential tumor suppressor function. This is achieved through the upregulation of the p53 family member, p73, and its target genes, which are involved in cell cycle control and apoptosis (Hanks2011Pleomorphic). PLAGL2 expression leads to an increase in TAp73 mRNA, indicating that it may regulate p73 transcription, possibly through direct binding to the p73 promoter (Hanks2011Pleomorphic).

PLAGL2 is also known to activate the expression of proapoptotic proteins such as Nip3, which can dimerize with Bcl-2, a regulator of apoptosis. This activity is independent of the hypoxia-inducible factor-1 (HIF-1) pathway, suggesting a distinct role for PLAGL2 in apoptosis (Mizutani2002A). The gene is expressed in response to hypoxia or iron deficiency, conditions that can lead to apoptosis, further supporting its role in regulating cell death and proliferation under stress conditions (Mizutani2002A).

## Clinical Significance
PLAGL2 (PLAG1 like zinc finger 2) is implicated in various cancers due to its role in promoting oncogenic pathways. In high-grade gliomas, particularly glioblastoma multiforme (GBM), high PLAGL2 expression is associated with poor prognosis. It is linked to increased tumor proliferation, migration, and angiogenesis, with the VEGF-VEGFR2 signaling pathway notably activated in patients with elevated PLAGL2 levels (Wang2022High). PLAGL2 is also overexpressed in colorectal cancer and acute myeloid leukemia (AML), where it is associated with specific cytogenetic subgroups, such as inv(16) AML (Landrette2005Plag1).

In gastric cancer, PLAGL2 promotes cell proliferation and migration, with high expression levels correlating with poor overall survival and increased metastatic potential (Wu2021PLAGL2). In lung adenocarcinoma, PLAGL2 expression is linked to tumorigenesis and emphysema, a risk factor for lung cancer. It may influence progenitor cell expansion in the lungs, contributing to oncogenesis (Yang2011Pleiomorphic).

PLAGL2's oncogenic activity is also observed in gliomas, where it enhances anchorage-independent growth and invasive capacity, suggesting its role in tumor maintenance (Zheng2010PLAGL2). These findings highlight PLAGL2's significant role in cancer progression and its potential as a prognostic marker.

## Interactions
PLAGL2 interacts with several proteins and nucleic acids, playing a significant role in transcriptional regulation. It interacts with Ubc9, a SUMO conjugating enzyme, which enhances PLAGL2's transactivation activity on the SP-C promoter independently of SUMOylation. This interaction suggests that Ubc9 acts as a co-activator for PLAGL2 (Guo2008Modulation).

PLAGL2 also interacts with Tip60, a transcription cofactor with acetyltransferase activity. Tip60 enhances PLAGL2-mediated transactivation by acetylating PLAGL2, which prevents its sumoylation. This interaction is mediated by the zinc finger domain of Tip60 and is crucial for modulating PLAGL2's activity on specific promoters, such as the IGFII promoter (Ning2007Tip60).

In the context of bladder cancer, PLAGL2 interacts with the Hippo/YAP1 signaling pathway. It activates YAP1 by inhibiting the Hippo pathway, leading to increased nuclear translocation of YAP1 and TAZ, and upregulation of downstream target genes. This interaction promotes cancer progression by enhancing cell proliferation and migration (Chen2023PLAGL2).

PLAGL2 also forms a complex with PC2, a component of the ARC/Mediator complex, which is essential for the cooperative activation of the NCF2 promoter (Wezensky2010Modulation).


## References


[1. (Guo2008Modulation) Yuhong Guo, Meng-Chun W. Yang, Jonathan C. Weissler, and Yih-Sheng Yang. Modulation of plagl2 transactivation activity by ubc9 co-activation not sumoylation. Biochemical and Biophysical Research Communications, 374(3):570–575, September 2008. URL: http://dx.doi.org/10.1016/j.bbrc.2008.07.064, doi:10.1016/j.bbrc.2008.07.064. This article has 15 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.bbrc.2008.07.064)

[2. (Zheng2005Sumoylation) Gang Zheng and Yu-Chung Yang. Sumoylation and acetylation play opposite roles in the transactivation of plag1 and plagl2*. Journal of Biological Chemistry, 280(49):40773–40781, December 2005. URL: http://dx.doi.org/10.1074/jbc.M504334200, doi:10.1074/jbc.m504334200. This article has 41 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1074/jbc.M504334200)

[3. (Hanks2011Pleomorphic) Tracey S. Hanks and Katherine A. Gauss. Pleomorphic adenoma gene-like 2 regulates expression of the p53 family member, p73, and induces cell cycle block and apoptosis in human promonocytic u937 cells. Apoptosis, 17(3):236–247, November 2011. URL: http://dx.doi.org/10.1007/s10495-011-0672-3, doi:10.1007/s10495-011-0672-3. This article has 15 citations and is from a peer-reviewed journal.](https://doi.org/10.1007/s10495-011-0672-3)

[4. (Ning2007Tip60) Jinying Ning, Gang Zheng, and Yu‐Chung Yang. Tip60 modulates plagl2‐mediated transactivation by acetylation. Journal of Cellular Biochemistry, 103(3):730–739, June 2007. URL: http://dx.doi.org/10.1002/jcb.21444, doi:10.1002/jcb.21444. This article has 9 citations and is from a peer-reviewed journal.](https://doi.org/10.1002/jcb.21444)

[5. (Zheng2010PLAGL2) Hongwu Zheng, Haoqiang Ying, Ruprecht Wiedemeyer, Haiyan Yan, Steven N. Quayle, Elena V. Ivanova, Ji-Hye Paik, Hailei Zhang, Yonghong Xiao, Samuel R. Perry, Jian Hu, Anant Vinjamoori, Boyi Gan, Ergun Sahin, Milan G. Chheda, Cameron Brennan, Y. Alan Wang, William C. Hahn, Lynda Chin, and Ronald A. DePinho. Plagl2 regulates wnt signaling to impede differentiation in neural stem cells and gliomas. Cancer Cell, 17(5):497–509, May 2010. URL: http://dx.doi.org/10.1016/j.ccr.2010.03.020, doi:10.1016/j.ccr.2010.03.020. This article has 209 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1016/j.ccr.2010.03.020)

[6. (Mizutani2002A) Atsushi Mizutani, Takako Furukawa, Yasushi Adachi, Susumu Ikehara, and Shigeru Taketani. A zinc-finger protein, plagl2, induces the expression of a proapoptotic protein nip3, leading to cellular apoptosis. Journal of Biological Chemistry, 277(18):15851–15858, May 2002. URL: http://dx.doi.org/10.1074/JBC.M111431200, doi:10.1074/jbc.m111431200. This article has 97 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1074/JBC.M111431200)

[7. (Kas1998Transcriptional) Koen Kas, Marianne L. Voz, Karen Hensen, Eva Meyen, and Wim J.M. Van de Ven. Transcriptional activation capacity of the novel plag family of zinc finger proteins. Journal of Biological Chemistry, 273(36):23026–23032, September 1998. URL: http://dx.doi.org/10.1074/jbc.273.36.23026, doi:10.1074/jbc.273.36.23026. This article has 117 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1074/jbc.273.36.23026)

[8. (Wang2022High) Gang Wang, Wei Du, Lingyi Che, Xianzheng Gao, Ruihua Zhao, Juan Duan, Zhuoyu Gu, and Qian Ma. High expression of plagl2 is associated with poor prognosis in high-grade glioma. Frontiers in Genetics, February 2022. URL: http://dx.doi.org/10.3389/fgene.2021.787746, doi:10.3389/fgene.2021.787746. This article has 2 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fgene.2021.787746)

[9. (Wezensky2010Modulation) Sara J. Wezensky, Tracey S. Hanks, Michelle J. Wilkison, Mary Cloud Ammons, Daniel W. Siemsen, and Katherine A. Gauss. Modulation of plagl2 transactivation by positive cofactor 2 (pc2), a component of the arc/mediator complex. Gene, 452(1):22–34, February 2010. URL: http://dx.doi.org/10.1016/j.gene.2009.12.003, doi:10.1016/j.gene.2009.12.003. This article has 10 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.gene.2009.12.003)

[10. (Wu2021PLAGL2) Liang Wu, Ning Zhao, Zili Zhou, Jinhuang Chen, Shengbo Han, Xudan Zhang, Haijun Bao, Wenzheng Yuan, and Xiaogang Shu. Plagl2 promotes the proliferation and migration of gastric cancer cells via usp37-mediated deubiquitination of snail1. Theranostics, 11(2):700–714, 2021. URL: http://dx.doi.org/10.7150/thno.47800, doi:10.7150/thno.47800. This article has 46 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.7150/thno.47800)

[11. (Yang2011Pleiomorphic) Yih-Sheng Yang, Meng-Chun W. Yang, and Jonathan C. Weissler. Pleiomorphic adenoma gene-like 2 expression is associated with the development of lung adenocarcinoma and emphysema. Lung Cancer, 74(1):12–24, October 2011. URL: http://dx.doi.org/10.1016/j.lungcan.2011.02.006, doi:10.1016/j.lungcan.2011.02.006. This article has 19 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.lungcan.2011.02.006)

[12. (Landrette2005Plag1) Sean F. Landrette, Ya-Huei Kuo, Karen Hensen, Sahar Barjesteh van Waalwijk van Doorn-Khosrovani, Paola N. Perrat, Wim J. M. Van de Ven, Ruud Delwel, and Lucio H. Castilla. Plag1 and plagl2 are oncogenes that induce acute myeloid leukemia in cooperation with cbfb-myh11. Blood, 105(7):2900–2907, April 2005. URL: http://dx.doi.org/10.1182/blood-2004-09-3630, doi:10.1182/blood-2004-09-3630. This article has 104 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1182/blood-2004-09-3630)

[13. (Chen2023PLAGL2) Hualin Chen, Wenjie Yang, Yingjie Li, and Zhigang Ji. Plagl2 promotes bladder cancer progression via racgap1/rhoa gtpase/yap1 signaling. Cell Death &amp; Disease, July 2023. URL: http://dx.doi.org/10.1038/s41419-023-05970-2, doi:10.1038/s41419-023-05970-2. This article has 8 citations.](https://doi.org/10.1038/s41419-023-05970-2)